AVLN (Avalyn Pharma) Ending Cash Position: $52.32 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AVLN Avalyn Pharma Inc AVLN
11 GF Score
Price $28.50
View Full Analysis

What is Avalyn Pharma Ending Cash Position?

Avalyn Pharma AVLN -1.01% 11 Ending Cash Position is $52.32 Mil as of Dec. 2025. GuruFocus rates AVLN with a GF Score™ of 11/100.

Avalyn Pharma's Ending Cash Position for the quarter that ended in Dec. 2025 was $52.32 Mil.

Avalyn Pharma's quarterly Ending Cash Position increased from . 20 ($0.00 Mil) to Dec. 2024 ($23.96 Mil) and increased from Dec. 2024 ($23.96 Mil) to Dec. 2025 ($52.32 Mil).

Avalyn Pharma's annual Ending Cash Position increased from . 20 ($0.00 Mil) to Dec. 2024 ($23.96 Mil) and increased from Dec. 2024 ($23.96 Mil) to Dec. 2025 ($52.32 Mil).

Avalyn Pharma Ending Cash Position Related Terms

Avalyn Pharma Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Avalyn Pharma's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avalyn Pharma Ending Cash Position Chart

Avalyn Pharma Annual Data
Trend Dec24 Dec25
Ending Cash Position
23.96 52.32

Avalyn Pharma Semi-Annual Data
Dec24 Dec25
Ending Cash Position 23.96 52.32
AVLN
11GF Score
Avalyn Pharma Inc AVLN
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Avalyn Pharma Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Avalyn Pharma's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=23.955+28.36
=52.32

Avalyn Pharma's Ending Cash Position for the quarter that ended in Dec. 2025 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=23.955+28.36
=52.32

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $52.32 Mil mean?
Avalyn Pharma (AVLN) has a Ending Cash Position of $52.32 Mil as of Dec. 2025. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Avalyn Pharma and its competitors.
Is Avalyn Pharma's Ending Cash Position too high?
Avalyn Pharma's current Ending Cash Position is $52.32 Mil. Overall, Avalyn Pharma has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Avalyn Pharma's Ending Cash Position compare to TRAX and IMTX?
Avalyn Pharma's Ending Cash Position of $52.32 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Avalyn Pharma and its competitors. Avalyn Pharma's current Ending Cash Position is $52.32 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avalyn Pharma stock overvalued right now?
Avalyn Pharma (AVLN) has a current Ending Cash Position of $52.32 Mil. The current Ending Cash Position is $52.32 Mil. Avalyn Pharma's overall GF Score™ is 11/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Avalyn Pharma (AVLN), the current Ending Cash Position is $52.32 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Avalyn Pharma Business Description

Address 105 W First Street, Boston, MA, USA, 02127
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.
11GF Score

Get the complete analysis for AVLN

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$28.50
Price